A Study of BGM0504 Injection in Participants With Obesity or Overweight

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Nov 27, 2025 to Mar 17, 2026
    • Enrollment target: estimated 620 to confirmed 652
    • Start date: Oct 28, 2024 to Oct 29, 2024
    • Eligibility criteria expanded, about 11 words
    • Site details revised
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an adjunct to diet, exercise, and behavioral interventions in overweight or obese non-diabetic adults in China for weight management, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.
Trial Details
NCT Number NCT06704581
Lead Sponsor BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Conditions
(from sponsor)		 Overweight or Obesity
Related terms Obesity, Overweight
Enrollment 652 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov